Hari P. Miskin
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 55
-
- Lymphoma Diagnosis and Treatment 29
- Hematology top 5%
- Immunology top 10%
- Immunodeficiency and Autoimmune Disorders 11
- Oncology top 10%
- CAR-T cell therapy research 8
-
- Monoclonal and Polyclonal Antibodies Research 17
-
- Acute Lymphoblastic Leukemia research 9
-
- Advanced Breast Cancer Therapies 8
-
- PI3K/AKT/mTOR signaling in cancer 7
- Co-authors
- Peter SportelliMichael WeissMarshall T. SchreederOwen A. O’ConnorChangchun DengJohn G. KuhnIan W. FlinnDanielle M. Brander
- Journals
- New England Journal of Medicine (1 paper)Journal of Clinical Oncology (13 papers)Blood (28 papers)
- Partner nations
- United StatesAustraliaPoland
In The Last Decade
Hari P. Miskin
63 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 56
- Genetics 699
- Pathology and Forensic Medicine 676
- Hematology 189
- Immunology 297
- Oncology 315
Countries citing papers authored by Hari P. Miskin
This map shows the geographic impact of Hari P. Miskin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hari P. Miskin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hari P. Miskin more than expected).
Fields of papers citing papers by Hari P. Miskin
This network shows the impact of papers produced by Hari P. Miskin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hari P. Miskin. The network helps show where Hari P. Miskin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hari P. Miskin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 4 | |
| 4 | 2023 | 1 | |
| 5 | TG-1701 A selective bruton tyrosine kinase (btk) inhibitor, as monotherapy and in combination with ublituximab and umbralisib (u2) in chronic lymphocytic leukemia (cll) and lymphoma | 2021 | 1 |
| 6 | 2021 | 39 | |
| 7 | 2020 | 8 | |
| 8 | 2019 | 64 | |
| 9 | 2019 | 56 | |
| 10 | 2018 | 90 | |
| 11 | 2018 | 1 | |
| 12 | 2017 | 61 | |
| 13 | 2017 | 4 | |
| 14 | 2016 | 44 | |
| 15 | 2016 | 2 | |
| 16 | 2016 | 9 | |
| 17 | 2015 | 11 | |
| 18 | 2014 | 8 | |
| 19 | 2014 | 13 | |
| 20 | 2012 | 4 |
About Hari P. Miskin
Hari P. Miskin is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology, having authored 66 papers that have together received 1.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (55 papers), Lymphoma Diagnosis and Treatment (29 papers), Monoclonal and Polyclonal Antibodies Research (17 papers), Immunodeficiency and Autoimmune Disorders (11 papers), Acute Lymphoblastic Leukemia research (9 papers), Advanced Breast Cancer Therapies (8 papers), CAR-T cell therapy research (8 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). The work is most often cited by research in Genetics (699 citations), Pathology and Forensic Medicine (676 citations) and Hematology (189 citations). Hari P. Miskin has collaborated with scholars based in United States, Australia and Poland. Frequent co-authors include Peter Sportelli, Michael Weiss, Marshall T. Schreeder, Owen A. O’Connor, Changchun Deng, John G. Kuhn, Ian W. Flinn, Danielle M. Brander, Swaroop Vakkalanka and Emmanuel Normant. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.